US 12,421,234 B1
Solid state forms
Mary Chaves, Arlington, MA (US); Patricia Lopez, Woodland Hills, CA (US); Prashant Agarwal, Chelsea, MA (US); Albert Amegadzie, Westlake Village, CA (US); Stephanie Azali, Woodland Hills, CA (US); Roman Shimanovich, Brighton, MA (US); Ron C. Kelly, Westlake Village, CA (US); and Darren Leonard Reid, Belmont, MA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Jun. 26, 2025, as Appl. No. 19/250,765.
Application 19/250,765 is a continuation of application No. 18/382,927, filed on Oct. 23, 2023.
Application 18/382,927 is a continuation of application No. 17/553,598, filed on Dec. 16, 2021, granted, now 11,827,635, issued on Nov. 28, 2023.
Application 17/553,598 is a continuation of application No. 16/878,824, filed on May 20, 2020, granted, now 11,236,091, issued on Feb. 1, 2022.
Claims priority of provisional application 62/851,044, filed on May 21, 2019.
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) [C07B 2200/13 (2013.01)] 29 Claims
 
1. A compound, wherein the compound is a crystalline form of the M atropisomer of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one (Compound 1) and wherein the compound is characterized by a powder X-ray diffraction pattern comprising peaks at 7.3, 9.8, 10.1, 11.3, 13.3, and 17.2±0.2 degrees 2 theta as measured by x-ray powder diffraction using an x-ray wavelength of 1.54 Å.